WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that the U.S. Patent and Trademark Office issued U.S. Patent 11,819,551 on November 21, 2023. The issued patent provides broad protection for Avilar’s first wave of extracellular proteins degraders called ATACs (ASGPR Targeting Chimeras) with therapeutic applications in a wide range of human diseases.

马萨诸塞州沃尔瑟姆（BUSINESS WIRE）-专注于细胞外蛋白质降解的生物制药公司Avilar Therapeutics今天宣布，美国专利商标局于2023年11月21日发布了美国专利11819551。已发布的专利为Avilar的第一波称为ATAC（ASGPR靶向嵌合体）的细胞外蛋白质降解物提供了广泛的保护，其在多种人类疾病中具有治疗应用。

ATACs are bi-functional molecules that leverage Avilar’s advanced chemistry for creating high-affinity ligands to the asialoglycoprotein receptor (ASGPR) and are designed to shuttle pathogenic extracellular proteins from circulation into the endolysosome where the unwanted proteins are degraded..

ATAC是双功能分子，可利用Avilar的先进化学方法为脱唾液酸糖蛋白受体（ASGPR）创建高亲和力配体，并设计用于将致病性细胞外蛋白从循环中穿梭到不需要的蛋白降解的溶酶体中。。

“We are excited to receive this U.S. patent as one of the cornerstones in our growing intellectual property estate,” commented Daniel Grau, CEO of Avilar. “This patent underscores the creativity and expertise of Avilar scientists, who conceived and developed new and improved ASGPR ligand chemistry. The resulting novel ligands provide the backbone for Avilar’s ATAC extracellular degraders and offer advantages versus previous approaches, including our ability to achieve high levels of protein degradation using lower molecular weight monovalent compounds.”.

Avilar首席执行官Daniel Grau评论说：“我们很高兴将这项美国专利作为我们不断增长的知识产权领域的基石之一。”。“这项专利强调了Avilar科学家的创造力和专业知识，他们构思并开发了新的和改进的ASGPR配体化学。由此产生的新型配体为Avilar的ATAC细胞外降解物提供了骨架，并提供了优于以前方法的优势，包括我们实现高水平使用较低分子量单价co的蛋白质降解化合物”。

Avilar has successfully demonstrated in vivo proof-of-concept for ATACs as potent degraders of extracellular proteins. At previous scientific conferences, Avilar presented data for ATACs that bind to and degrade immunoglobulin G (IgG). In a repeat dose study in non-human primates conducted by Avilar, a novel monovalent ATAC formulated in a simple subcutaneous injection demonstrated 85% reduction in IgG.

Avilar已经成功地证明了ATACs作为细胞外蛋白质有效降解物的体内概念验证。在之前的科学会议上，Avilar提供了结合并降解免疫球蛋白G（IgG）的ATAC数据。在由Avilar进行的非人灵长类动物的重复剂量研究中，在简单皮下注射中配制的新型单价ATAC显示IgG减少85%。

IgG is the second most abundant protein in the human body and reduction of pathogenic IgG autoantibodies is a clinically validated strategy for treating multiple debilitating autoimmune diseases..

IgG是人体中第二丰富的蛋白质，致病性IgG自身抗体的减少是治疗多种使人衰弱的自身免疫疾病的临床验证策略。。

About Avilar Therapeutics

关于Avilar疗法

Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded.

Avilar Therapeutics是一家生物制药公司，开创了细胞外蛋白质降解物的发现和开发，这是靶向蛋白质降解的新前沿。Avilar开发ATACs（ASGPR靶向嵌合体），这是一类新型蛋白质降解剂，可将致病蛋白质从循环中穿梭到内溶酶体，在那里不需要的蛋白质被降解。

Avilar has built a proprietary discovery platform that includes novel, high-affinity, small molecule ASGPR (asialoglycoprotein receptor) ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. This platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases.

Avilar建立了一个专有的发现平台，包括新颖的，高亲和力的小分子ASGPR（去唾液酸糖蛋白受体）配体以及ATAC介导的内吞作用和降解的生物物理学，药代动力学和药效学的高级建模。该平台能够模块化设计和合成可跨越细胞外蛋白质组延伸至涉及人类疾病发病机理的各种蛋白质的ATAC。

Avilar is leveraging its ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar is based in Waltham, MA. For more information, please visit www.avilar-tx.com and follow us on LinkedIn..

Avilar正在利用其ATAC平台创建一流的细胞外蛋白质降解物的广泛而多样的管道。Avilar总部设在马萨诸塞州沃尔瑟姆。有关更多信息，请访问www.Avilar-tx.com并通过LinkedIn跟进我们。。